207 related articles for article (PubMed ID: 38562613)
1. Lipid Nanoparticle-Based Inhibitors for SARS-CoV-2 Host Cell Infection.
Yathindranath V; Safa N; Tomczyk MM; Dolinsky V; Miller DW
Int J Nanomedicine; 2024; 19():3087-3108. PubMed ID: 38562613
[TBL] [Abstract][Full Text] [Related]
2. Lipid nanoparticle formulations for optimal RNA-based topical delivery to murine airways.
Tam A; Kulkarni J; An K; Li L; Dorscheid DR; Singhera GK; Bernatchez P; Reid G; Chan K; Witzigmann D; Cullis PR; Sin DD; Lim CJ
Eur J Pharm Sci; 2022 Sep; 176():106234. PubMed ID: 35688311
[TBL] [Abstract][Full Text] [Related]
3. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
Li K; Meyerholz DK; Bartlett JA; McCray PB
mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
[TBL] [Abstract][Full Text] [Related]
4. Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity.
Essalmani R; Jain J; Susan-Resiga D; Andréo U; Evagelidis A; Derbali RM; Huynh DN; Dallaire F; Laporte M; Delpal A; Sutto-Ortiz P; Coutard B; Mapa C; Wilcoxen K; Decroly E; Nq Pham T; Cohen ÉA; Seidah NG
J Virol; 2022 Apr; 96(8):e0012822. PubMed ID: 35343766
[TBL] [Abstract][Full Text] [Related]
5. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.
Day CJ; Bailly B; Guillon P; Dirr L; Jen FE; Spillings BL; Mak J; von Itzstein M; Haselhorst T; Jennings MP
mBio; 2021 Mar; 12(2):. PubMed ID: 33785634
[TBL] [Abstract][Full Text] [Related]
6. In silico investigation of critical binding pattern in SARS-CoV-2 spike protein with angiotensin-converting enzyme 2.
Jafary F; Jafari S; Ganjalikhany MR
Sci Rep; 2021 Mar; 11(1):6927. PubMed ID: 33767306
[TBL] [Abstract][Full Text] [Related]
7. Nonmuscle myosin heavy chain IIA facilitates SARS-CoV-2 infection in human pulmonary cells.
Chen J; Fan J; Chen Z; Zhang M; Peng H; Liu J; Ding L; Liu M; Zhao C; Zhao P; Zhang S; Zhang X; Xu J
Proc Natl Acad Sci U S A; 2021 Dec; 118(50):. PubMed ID: 34873039
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 deregulates the vascular and immune functions of brain pericytes via Spike protein.
Khaddaj-Mallat R; Aldib N; Bernard M; Paquette AS; Ferreira A; Lecordier S; Saghatelyan A; Flamand L; ElAli A
Neurobiol Dis; 2021 Dec; 161():105561. PubMed ID: 34780863
[TBL] [Abstract][Full Text] [Related]
9. Lipid nanoparticle-encapsulated mRNA antibody provides long-term protection against SARS-CoV-2 in mice and hamsters.
Deng YQ; Zhang NN; Zhang YF; Zhong X; Xu S; Qiu HY; Wang TC; Zhao H; Zhou C; Zu SL; Chen Q; Cao TS; Ye Q; Chi H; Duan XH; Lin DD; Zhang XJ; Xie LZ; Gao YW; Ying B; Qin CF
Cell Res; 2022 Apr; 32(4):375-382. PubMed ID: 35210606
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 and SARS-CoV Spike-Mediated Cell-Cell Fusion Differ in Their Requirements for Receptor Expression and Proteolytic Activation.
Hörnich BF; Großkopf AK; Schlagowski S; Tenbusch M; Kleine-Weber H; Neipel F; Stahl-Hennig C; Hahn AS
J Virol; 2021 Apr; 95(9):. PubMed ID: 33608407
[TBL] [Abstract][Full Text] [Related]
11. Luteolin inhibits spike protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) binding to angiotensin-converting enzyme 2.
Zhu J; Yan H; Shi M; Zhang M; Lu J; Wang J; Chen L; Wang Y; Li L; Miao L; Zhang H
Phytother Res; 2023 Aug; 37(8):3508-3521. PubMed ID: 37166054
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of SARS-CoV-2 pseudovirus invasion by ACE2 protecting and Spike neutralizing peptides: An alternative approach to COVID19 prevention and therapy.
Chen J; Li S; Lei Z; Tang Q; Mo L; Zhao X; Xie F; Zi D; Tan J
Int J Biol Sci; 2021; 17(11):2957-2969. PubMed ID: 34345219
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of SARS-CoV-2 viral entry upon blocking N- and O-glycan elaboration.
Yang Q; Hughes TA; Kelkar A; Yu X; Cheng K; Park S; Huang WC; Lovell JF; Neelamegham S
Elife; 2020 Oct; 9():. PubMed ID: 33103998
[TBL] [Abstract][Full Text] [Related]
14. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies.
Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R
J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866
[TBL] [Abstract][Full Text] [Related]
15. GMI, a protein from Ganoderma microsporum, induces ACE2 degradation to alleviate infection of SARS-CoV-2 Spike-pseudotyped virus.
Yeh H; Vo DNK; Lin ZH; Ho HPT; Hua WJ; Qiu WL; Tsai MH; Lin TY
Phytomedicine; 2022 Aug; 103():154215. PubMed ID: 35691077
[TBL] [Abstract][Full Text] [Related]
16. An angiotensin-converting enzyme-2-derived heptapeptide GK-7 for SARS-CoV-2 spike blockade.
Han S; Zhao G; Wei Z; Chen Y; Zhao J; He Y; He YJ; Gao J; Chen S; Du C; Wang T; Sun W; Huang Y; Wang C; Wang J
Peptides; 2021 Nov; 145():170638. PubMed ID: 34419496
[TBL] [Abstract][Full Text] [Related]
17. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
18. Shedding Light on the Inhibitory Mechanisms of SARS-CoV-1/CoV-2 Spike Proteins by ACE2-Designed Peptides.
Freitas FC; Ferreira PHB; Favaro DC; Oliveira RJ
J Chem Inf Model; 2021 Mar; 61(3):1226-1243. PubMed ID: 33619962
[TBL] [Abstract][Full Text] [Related]
19. Withanone from
Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, evaluation, and mechanism of 1-(4-(arylethylenylcarbonyl)phenyl)-4-carboxy-2-pyrrolidinones as potent reversible SARS-CoV-2 entry inhibitors.
Palla SR; Li CW; Chao TL; Lo HV; Liu JJ; Pan MY; Chiu YT; Lin WC; Hu CW; Yang CM; Chen YY; Fang JT; Lin SW; Lin YT; Lin HC; Kuo CJ; Wang LH; Chang SY; Liang PH
Antiviral Res; 2023 Nov; 219():105735. PubMed ID: 37858764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
